United States - English - NLM (National Library of Medicine)

mission pharmacal company - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), iron (unii: e1uol152h7) (iron - unii:e1uol152h7), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), alpha-tocopherol (unii: h4n855pnz1) (alpha-tocopherol - unii:h4n855pnz1), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), folic acid (unii: 935e97boy8) (folic a - citranatal essence tm is a multivitamin/mineral prescription drug indicated for use in improving the nutritional status of women prior to conception, throughout pregnancy, and in the postnatal period for both lactating and nonlactating mothers. this product is contraindicated in patients with a known hypersensitivity to any of the ingredients.

United States - English - NLM (National Library of Medicine)

mission pharmacal company - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), vitamin d (unii: 9vu1ki44gp) (cholecalciferol - unii:1c6v77qf41), iron (unii: e1uol152h7) (iron - unii:e1uol152h7), .alpha.-tocopherol acetate (unii: 9e8x80d2l0) (.alpha.-tocopherol - unii:h4n855pnz1), thiamine (unii: x66nso3n35) (thiamine ion - unii:4abt0j945j), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), pyridoxine hydrochloride (unii: 68y4cf58bv) (p - ascorbic acid 120 mg - citranatal ® dha is a multi-vitamin/mineral prescription drug indicated for use in improving the nutritional status of women prior to conception, throughout pregnancy, and in the postnatal period for both lactating and nonlactating mothers. this product is contraindicated in patients with a known hypersensitivity to any of the ingredients.

United States - English - NLM (National Library of Medicine)

mission pharmacal company - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), calcium citrate (unii: mlm29u2x85) (calcium cation - unii:2m83c4r6zb), iron (unii: e1uol152h7) (iron - unii:e1uol152h7), vitamin d (unii: 9vu1ki44gp) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol acetate (unii: 9e8x80d2l0) (.alpha.-tocopherol - unii:h4n855pnz1), thiamine (unii: x66nso3n35) (thiamine ion - unii:4abt0j945j), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), niacinamide (unii: 25x51i8rd4) (niacina - ascorbic acid 120 mg - [insert clinical pharmacology general text here] [insert mechanism of action text here]

United States - English - NLM (National Library of Medicine)

hi-tech pharmacal co., inc. - hydroxyzine hydrochloride (unii: 76755771u3) (hydroxyzine - unii:30s50ym8og) - hydroxyzine hydrochloride 10 mg in 5 ml - for symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus. as a sedative when used as premedication and following general anesthesia, hydroxyzine may potentiate meperidine (demerol® ) and barbiturates , so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. atropine and other belladonna alkaloids are not affected by the drug. hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. the effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. the physician should reassess periodically the usefulness of the drug for the individual patient. oral hydroxyzine hyd

United States - English - NLM (National Library of Medicine)

hi-tech pharmacal co., inc. - morphine (unii: 76i7g6d29c) (morphine - unii:76i7g6d29c) - morphine 2 mg in 5 ml - paregoric is useful for the treatment of diarrhea. hypersensitivity to morphine. because of its stimulating effect on the spinal cord, morphine should not be used in convulsive states, such as those occurring in status epilepticus, tetanus, and strychnine poisoning. this preparation should not be used in diarrhea caused by poisoning until the toxic material is eliminated from the gastrointestinal tract. paregoric is a schedule lll narcotic. morphine can produce drug dependence and, therefore, has the potential for being abused. patients receiving therapeutic dosage regimens of 10 mg every 4 hours for 1 to 2 weeks have exhibited mild withdrawal symptoms. development of the dependent state is recognizable by an increased tolerance to the analgesic effect and the appearance of purposive phenomena (complaints, pleas, demands, or manipulative actions) shortly before the time of the next scheduled dose. a patient in withdrawal should be treated in a hospital environment. usually, it is necessary only to provide sup

United States - English - NLM (National Library of Medicine)

blenheim pharmacal, inc. - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride 750 mg - because of reports of intestinal and gastric ulceration and bleeding with controlled-release potassium chloride preparations, these drugs should be reserved for those patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations, or for patients with whom there is a problem of compliance with these preparations. the use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern, and when low doses of the diuretic are used. serum potassium should be checked periodically, however, and, if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. in more severe cases and if dose adjustment of the diuretic is ineffective or unwarranted supplementation with potassium salts may be indicated. potassium supplements are contraindicated in patients with hyperkalemia since a further increase in serum potassium concentration in s

United States - English - NLM (National Library of Medicine)

blenheim pharmacal, inc. - methocarbamol (unii: 125od7737x) (methocarbamol - unii:125od7737x) - methocarbamol 500 mg - methocarbamol tablets, usp are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. the mode of action of methocarbamol has not been clearly identified, but may be related to its sedative properties. methocarbamol does not directly relax tense skeletal muscles in man. methocarbamol tablets, usp are contraindicated in patients hypersensitive to methocarbamol or to any of the tablet components.

United States - English - NLM (National Library of Medicine)

mission pharmacal company - guaifenesin (unii: 495w7451vq) (guaifenesin - unii:495w7451vq), hydrocodone bitartrate (unii: no70w886kk) (hydrocodone - unii:6yks4y3wq7) - guaifenesin 200 mg in 5 ml - flowtuss is indicated for the symptomatic relief of cough and to loosen mucus associated with the common cold in patients 18 years of age and older. important limitations of use: - not indicated for pediatric patients under 18 years of age [ see use in specific populations (8.4) ]. - hypersensitivity to hydrocodone, guaifenesin, or any of the inactive ingredients in flowtuss [ see adverse reactions (6) ]. teratogenic effects pregnancy category c there are no adequate and well controlled studies of flowtuss in pregnant women. reproductive toxicity studies have not been conducted with flowtuss; however, studies are available with an individual active ingredient or related active ingredient. hydrocodone was teratogenic in hamsters. codeine, an opiate related to hydrocodone, increased resorptions and decreased fetal weight in rats. because animal reproduction studies are not always predictive of human response, flowtuss should be used during pregnancy only if the benefit justifies the potential risk to th

United States - English - NLM (National Library of Medicine)

blenheim pharmacal, inc. - hydroxyzine hydrochloride (unii: 76755771u3) (hydroxyzine - unii:30s50ym8og) - hydroxyzine hydrochloride 25 mg - for symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histamine-mediated pruritus. as a sedative when used as a premedication and following general anesthesia, hydroxyzine may potentiate meperidine and barbiturates, so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. atropine and other belladonna alkaloids are not affected by the drug. hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. the effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. the physician should reassess periodically the usefulness of the drug for the individual patient. hydroxyzine, when administered t

United States - English - NLM (National Library of Medicine)

hi-tech pharmacal co., inc. - protriptyline hydrochloride (unii: 44665v00o8) (protriptyline - unii:4ndu154t12) - protriptyline hydrochloride 5 mg - protriptyline hydrochloride tablets are indicated for the treatment of symptoms of mental depression in patients who are under close medical supervision. its activating properties make it particularly suitable for withdrawn and anergic patients. protriptyline hydrochloride tablets are contraindicated in patients who have shown prior hypersensitivity to it. it should not be given concomitantly with a monoamine oxidase inhibiting compound. hyperpyretic crises, severe convulsions, and deaths have occurred in patients receiving tricyclic antidepressant and monoamine oxidase inhibiting drugs simultaneously. when it is desired to substitute protriptyline for a monoamine oxidase inhibitor, a minimum of 14 days should be allowed to elapse after the latter is discontinued. protriptyline should then be initiated cautiously with gradual increase in dosage until optimum response is achieved. protriptyline is contraindicated in patients taking cisapride because of the possibility of adverse cardiac interactions includ